TargetMol

Cgp 6809

Product Code:
 
TAR-T30842
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T30842-5mg5mg£1,171.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30842-50mg50mg£2,303.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30842-100mg100mg£3,042.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Cgp 6809 is a new methylnitrosoureido-sugar derivative that has been shown to be active against a broad spectrum of transplantable tumours in mice and rats. CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer.
CAS:
84069-38-5
Formula:
C12H23N3O7
Molecular Weight:
321.33
Purity:
0.98
SMILES:
CCO[C@H]1O[C@H]([C@@H](CNC(=O)N(C)N=O)OC)[C@H](OC)[C@H]1O

References

1. Creaven PJ, Cowens JW, Huben R, Petrelli N, Karakousis C, Traynor D. Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks. Cancer Chemother Pharmacol. 1989;23(4):266-7. PubMed PMID: 2924383. 2. Schieweck K, Stanek J, Kanter PM, Schmidt-Ruppin KH, M?ller M, Matter A. CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties. Cancer Chemother Pharmacol. 1989;23(6):341-7. PubMed PMID: 2713956. 3. Fiebig HH, Widmer KH, Winterhalter BR, L?hr GW. CGP 6809--a new nitrosoureido-sugar derivative with activity in human tumor xenografts. Cancer Chemother Pharmacol. 1989;23(6):337-40. PubMed PMID: 2713955. 4. Creaven PJ, Madajewicz S, Cowens JW, Plager JE, Pendyala L, Mittelman A, Petrelli N, Karakousis C, Huben R, Takita H, et al. Phase I clinical trial of ethyl 6-deoxy-3,5-di-O-methyl 6-(3 methyl-3-nitrosoureido)-alpha-D-glucofuranoside (CGP 6809). Cancer Chemother Pharmacol. 1987;20(1):37-40. PubMed PMID: 3304687.